RECRUITINGOBSERVATIONAL

A Non-interventional Registry for Patients with Hepatitis B Virus Infection

The European HBV Registry: a Joint Initiative of TherVacB and DZIF

About This Trial

In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials. Extensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies. Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).

Who May Be Eligible (Plain English)

Who May Qualify: - Hepatitis B Virus Infection TherVacB sub-cohort: - confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion - HBeAg status documented for at least 6 months Who Should NOT Join This Trial: TherVacB sub-cohort: - age \>70 years - co-infection with HIV, HCV (RNA positive), - clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.) - significant comorbidities (e.g. malignancies) - immunosuppressive treatment (\> 40 mg Cortisol- equivalent) - liver cirrhosis (judged clinically or based on ultrasound/transient elastography) - History of hepatocellular carcinoma Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Hepatitis B Virus Infection TherVacB sub-cohort: * confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion * HBeAg status documented for at least 6 months Exclusion Criteria: TherVacB sub-cohort: * age \>70 years * co-infection with HIV, HCV (RNA positive), * clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.) * significant comorbidities (e.g. malignancies) * immunosuppressive treatment (\> 40 mg Cortisol- equivalent) * liver cirrhosis (judged clinically or based on ultrasound/transient elastography) * History of hepatocellular carcinoma

Treatments Being Tested

OTHER

No intervention

Locations (1)

Hannover Medical School

Hanover, Germany